Entasis Therapeutics : to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming H.C. Wainwright 23^rd Annual Global Investment Conference. Details of the Company’s participation are as follows:

Conference: H.C. Wainwright 23rd Annual Global Investment Conference
Dates: September 13-15, 2021
Format:	Fireside chat available on-demand beginning September 13th at 7:00am ET
	One-on-one investor meetings

About Entasis
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0462 (targeting multiple Gram-negative pathogens including Pseudomonas aeruginosa) and ETX0282CPDP (targeting Enterobacteriaceae infections). For more information, visit www.entasistx.com.

Entasis Contacts         
Company:
Kyle Dow
Entasis Therapeutics
[phone]
[e-mail]

Investor Relations:
Bruce Mackle
LifeSci Advisors
[phone]
[e-mail]

Source: Entasis Therapeutics Holdings Inc.

2021 GlobeNewswire, Inc., source Press Releases